A BaS T R A C T The acute effects of intravenous (i.v.) probenecid and chlorothiazide on renal urate handling were investigated in paired studies in normal men. Uricosuric responses to these agents were compared in the same subjects, both without and with pyrazinamide (PZA) pretreatment. Assuming that PZA selectively inhibits the tubular secretion of urate and that uricosuric agents act by increasing the excretion of filtered urate, then the uricosuric responses (the increment in urate excretion or clearance) should have been unaffected by PZA. Defined in this manner, however, uricosuric responses to probenecid and chlorothiazide were significantly decreased after PZA pretreatment. In order to determine whether PZA diminished other renal actions of chlorothiazide, changes in sodium and inorganic phosphorus excretion were examined. Chlorothiazide produced equivalent natriuretic and phosphaturic responses after PZA pretreatment, indicating that PZA does not interfere with at least some of the renal actions of chlorothiazide. In separate studies, PZA depressed urate excretion by at least 68% during the maintenance of chlorothiazide-induced natriuresis and phosphaturia, suggesting that chlorothiazide does not diminish the antisecretory action of PZA.
INTRODUCTION
The mechanism of action of uricosuric agents has been a matter of considerable theoretical and practical interest, but has been difficult to study in man. After the demonstration that pyrazinamide (PZA)' and pyrazinoic acid are potent and highly selective inhibitors of the renal tubular secretion of urate in several species (1) (2) (3) , PZA subsequently was utilized to give a rough quantitative estimate of the relative magnitudes of urate reabsorption and secretion in man (4, 5) . In the "PZA suppression test," the decrement in uric acid excretion produced by a maximally antiuricosuric dose of PZA is taken as an index of tubular secretion, while the residual amount of urinary urate after PZA usually is considered to represent urinary uric acid derived from glomerular filtration but escaping tubular reabsorption (6) . This interpretation depends on the assumptions that: (a) PZA completely and specifically inhibits urate secretion, and (b) there is no interaction between urate secretion and reabsorption within the nephron. If the action of PZA were incomplete or nonspecific, or if a portion of the secreted urate subsequently were reabsorbed, the PZA technique would underestimate both tubular secretion and reabsorption.
The present studies were designed to further examine changes in renal urate handling in man during the uricosuric states immediately after the administration of probenecid and chlorothiazide. The increased uric acid excretion caused by uricosuric agents usually has been attributed solely to an increase in the fraction of filtered urate excreted. In contrast, the results of the present studies indirectly suggest that the increased excretion of secreted urate may contribute importantly to the uricosuric properties of probenecid and chlorothiazide.
METHODS
38 renal clearance studies were performed in 21 volunteers. All had been fully informed of the experimental nature of the studies and gave their informed consent. None had a history of gout. 19 subjects were normal males whose ages ranged from 20 to 35 yr. One female participant, R. O., age 54, had essential hypertension; while the other, J. S., age 46, had bilateral renal artery stenosis.
'Abbreviations used in this paper: Cinuiln, clearance of inulin; GFR, glomerular filtration rate; PAH, para-aminohippuric; PZA, pyrazinamide. (27) (0.5) (1.1)
Probenecid-mean The subjects were studied as outpatients, and had been consuming their usual diets. None were taking medications. Studies commenced in the morning after an overnight fast. Venous blood specimens were drawn into heparinized syringes from an indwelling needle at the midpoint of each clearance period. Urine specimens were obtained by voiding; all exceeded 70 ml in volume. Participants remained recumbent throughout, except while voiding. Initial hydration was accomplished with tap water, 10-15 ml/kg orally, as well as the intravenous (iv.) administration of 1,000 ml of 0.45%o NaCl during a 40-60 min equilibration interval preceding the onset of clearance periods. After the administration of a suitable priming dose of inulin, a sustaining infusion of inulin in 0.9%o NaCl was maintained at 3.5 ml/min, utilizing an infusion pump. Four subjects also received para-aminohippurate (PAH) in amounts sufficient to establish plasma concentrations at 5-10 mg/100 ml, levels which do not affect urate excretion in man (7) . Clearance periods were 20 min in duration. Specimens for 3 or 4 control clearance periods were collected at the beginning of each experiment.
In 34 experiments in 17 normal participants, subjects received 500 mg of probenecid or chlorothiazide as a single i.v. pulse. Specimens for three additional clearance periods then were collected. After an interval ranging from 3 to 31 days, the studies were repeated in an identical manner in the same participants, except that each received PZA, 3 g orally, 90 min before onset of the control periods for the second study. In four other studies with chlorothiazide, participants received 3 g of PZA orally after completion of the above experimental sequence without PZA. The format then was repeated, beginning with infusion of 1,000 ml of 0.45% NaCI during another equilibration interval, during which the antiuricosuric action of PZA developed.
Inulin (8) and inorganic phosphorus (9) were analyzed by automated methods. Uric acid was measured by an ultraviolet enzymatic spectrophotometric procedure (10) or an automated differential enzymatic colorimetric procedure (11) . The latter method does not require dialysis of samples or precipitation of plasma proteins. Both methods gave substantially identical results and complete recoveries of uric acid in plasma and urine. Sodium was measured with a flame photometer, utilizing lithium internal standardization.
The clearance of inulin (Cinuii.) was used as an estimate of glomerular filtration rate (GFR). Values for GFR, urine flow rate, and solute excretion rates were normalized to a standard body surface area of 1.73 m2. In each study, results from all control periods and all posturicosuric periods were averaged separately. Comparisons were made utilizing paired t tests (12) . Mean control values were compared with mean posturicosuric values as pairs in each experiment. In addition, paired comparisons were made between similar phases for experiments in the same participants, without and with PZA pretreatment.
RESULTS
Uricosuric responses to probenecid, 500 mg i.v., were measured in paired experiments in seven normal men without and with PZA pretreatment (Table I) Roughly similar changes occurred in urate excretion per unit GFR (Fig. 1) and Curate/Cinulin (Fig. 2) . GFR tended to diminish and urine flow increased after chlorothiazide (Table II) .
In the probenecid studies without PZA, the increase in urate clearance (ACurato/Cinulin) averaged 18.4±2.1 ml/100 ml GFR (mean difference ±SEM of the paired differences), in contrast to a ACurate/Cinulin of 4.1±0.6 ml/100 ml GFR in the probenecid studies with PZA (P < 0.001 for the paired comparisons of ACurate/ CGnui n). Similarly, in the chlorothiazide studies without PZA, ACurate/Cinulln averaged 9.6±1.2 ml/100 ml GFR, in contrast to 4.9±0.8 ml/100 ml GFR with PZA (P < 0.02 for paired comparisons). In the experiments without PZA pretreatment, the mean uricosuric response to probenecid (ACurate/CilnulIn) was 92% greater than to chlorothiazide. After PZA, the uricosuric responses to both agents were similar. Thus, chlorothiazide appeared to be as potent a uricosuric agent as probenecid when comparisons were made after PZA pretreatment (Fig.  2) .
Plasma urate values in both types of paired studies were comparable (Table III) . In G. U. (Table I) , the plasma urate was 8.4 mg/100 ml in the study without PZA, but unaccountably had diminished to 5.2 mg/100 ml 3 days later when the PZA study was performed. In all other participants, plasma urate concentrations were less than 7 mg/100 ml. Likewise, plasma sodium and inorganic phosphorus values did not vary significantly between the groups (Table III) .
The suppression of uricosuric responses to probenecid and chlorothiazide after PZA pretreatment could have resulted from some type of interference by PZA with the renal transport or actions of these compounds. In the case of chlorothiazide, its natriuretic and phosphaturic actions were compared, both without and with PZA pretreatment (Table IV) . Changes in fractional sodium excretion (ACNa/Ctnuit) and fractional inorganic phosphorus excretion (ACphosphate/Clnul n) were essentially equivalent in the paired studies (Fig. 3) . Control values for both parameters were similar, without and with PZA pretreatment (Table IV) . ACNa/CInU t1 after chlorothiazide averaged 5.1±0.8 ml/100 ml GFR without PZA and 6.3±0.4 ml/100 ml GFR with PZA values which did not differ significantly (Fig. 3) . Similarly, ACphosphate/ Cinuiin averaged 13.2±1.0 ml/100 ml GFR without PZA and 14.5±0.9 ml/100 ml GFR with PZA (Fig. 3) .
Although the uricosuric action of chlorothiazide was sharply diminished after PZA pretreatment, its natri- uretic and phosphaturic properties were unaffected (Table IV).
Since the uricosuric responses to chlorothiazide in PZA pretreated subjects might have resulted from interference by chlorothiazide with the antiuricosuric properties of PZA, the peak antiuricosuric effect of PZA after receiving chlorothiazide was investigated in four additional combined studies (Table V) . At the time of the peak antiuricosuric action of PZA, fractional sodium excretion (CNa/Cinulin) and fractional phosphorus excretion (Cphosphate/Cinul i) had declined somewhat from their respective peak values after the initial dose of chlorothiazide, but still greatly exceeded their original control values. Concomitantly, however, urate excretion (per unit GFR) decreased to values ranging from 68% to 90% less than control, comparing favorably with values reported previously in the absence of chlorothiazide (4). When a second dose of chlorothiazide was administered, the peak increment in uricosuric response was less than that after the first dose of chlorothiazide in all the subjects except S. T., although there always was a definite uricosuric response after the second dose. Likewise, fractional sodium and phosphorus excretion increased after the second dose of chlorothiazide. The PZAinduced discrepancies in peak uricosuric responses, with both experimental phases performed during the same day, suggest that the data of Table II did not arise from a Control, mean values during control periods; First chlorothiazide peak, values during peak uricosuric action of first dose of chlorothiazide; 500 mg i.v.,; PZA peak, values during peak antiuricosuric action of PZA (between 60 and 120 min after administration of PZA, 3 g.p.o.); Second chlorothiazide peak, values during peak uricosuric effect of second dose of chlorothiazide, 500 mg i.v., administered 120 min after PZA. Subjects received 1,000 ml 0.45% NaCl during the hour preceding the onset of control periods and during the 1st h after PZA administration.
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T. H. Steele and G. Boner systematic error incurred in performing the paired experiments on different days. DISCUSSION These data indicate a striking diminution in uricosuric effects of probenecid and chlorothiazide in paired studies after PZA pretreatment. Assuming that PZA specifically and completely inhibited the tubular secretion of urate, only 22% of the uricosuric response to probenecid could be ascribed to an increase in the excretion of filtered urate, although nearly 70% of the response to chlorothiazide could be attributed to filtered urate. Although uricosuric agents may lessen the binding of urate to plasma proteins at low temperatures, the available data indicate that this protein-binding becomes negligible at normal body temperature (13) . Therefore, it seems unlikely that the results could be explained on the basis of PZA-induced alterations in the effects of chlorothiazide or probenecid on bound urate.
Evidence obtained in various species has suggested that the predominant effect of PZA or its active metabolite, pyrazinoic acid (14), is to inhibit the renal tubular secretion of urate (1-3). Fanelli, Bohn, and Stafford (15), in contrast, have suggested that pyrazinoate may increase the tubular reabsorption of urate rather than diminish its secretion. This possibility, however, seems unlikely in view of more recent observations in the dog (14) and chimpanzee (G. M. Fanelli, Jr., personal communication) wherein very large doses of pyrazinoic acid were uricosuric, in sharp contrast to the usual antiuricosuric action of the compound in those species (1, 3).
In addition, microinjection studies in the rat by Kramp, Lassiter, and Gottschalk (16) have indicated that pyrazinoate diminishes the proximal tubular outflux of [14Cl uric acid, although the total amount of uric acid present was not measured in those experiments. Therefore, it appears that PZA potentially could inhibit urate reabsorption in man, although in the doses used in these studies the predominant net effect is to inhibit secretion.
In addition to a lack of complete specificity of PZA, the PZA suppression test suffers from two other potential sources of inaccuracy. The dose of PZA (or the amount of pyrazinoic acid generated) might be insufficient to inhibit maximally the tubular secretion of urate. In that case, both urate secretion and reabsorption would be underestimated. If PZA simultaneously inhibited reabsorption in the doses utilized for the test, both parameters again would be underestimated. Another potential source of error, originally proposed by Gutman, is that a portion of the secreted urate might subsequently be reabsorbed (17) . Greger, Lang, and Deetjen (18) have reported net secretion of urate by proximal tubules of superficial nephrons in the rat while simultaneous urinary clearances of uric acid showed net reabsorption. The same authors have made measurements of unidirectional urate influx and efflux for the rat proximal tubule (19) . Again, the secretory flux was predominant in that nephron segment. If nephron homogeneity for uric acid handling in the rat is assumed, then those studies suggest that uric acid undergoes secretion before subsequent reabsorption in that species. Data supporting the proximal tubular secretion of uric acid also have been obtained in the mongrel dog, utilizing the stop-flow technique (20, 21) .
Recent evidence utilizing the PZA suppression technique suggests that a group of diverse uricosuric substances, disease states, and physiologic maneuvers, may increase the amount of secreted uric acid appearing in the urine. In man, glycine (22) , certain iodinated radiographic contrast agents (23) , ethacrynic acid (24) , and benziodarone (25) all have uricosuric actions which are diminished sharply or ablated entirely after pretreatment with PZA. In that respect, these diverse compounds affect renal urate handling similarly to probenecid and chlorothiazide. Also, the hyperuricosuric states accompanying certain cases of Wilson's Disease (26) and Hodgkin's Disease (27) (30) .
The data also are consistent with a diminished response to uricosuric agents in hyposecretory stateseither induced pharmacologically or by disease. If diuretic-induced hyperuricemia is due partially to diminished net urate secretion (24) , the uricosuric response to probenecid might be subnormal in that condition. Although previous data have suggested that probenecid is effective at ameliorating chronic diuretic-inducing hyperuricemia, no comparisons of uricosuric responses in normals and hyperuricemic patients were made (31) .
In far advanced chronic renal disease, net urate secretion per nephron usually appears to be severely compromised, as judged by the PZA suppression test (32) . The increased fraction of filtered urate excreted (after PZA) suggests that reabsorption also is impaired. In chronic lead nephropathy, however, PZA suppression has suggested a rather selective preservation of urate reabsorption-even in far advanced disease (33) . In view of the present data, it would be of considerable interest to compare uricosuric responses to probenecid in patients with lead nephropathy to responses in patients with other types of advanced renal disease. Similar studies also would be of interest in certain patients with gout who manifest a tendency toward sluggish excretion of urate, in contrast to other gouty patients with over-production of uric acid who do not exhibit this tendency (34) .
